VJOncology is committed to improving our service to you

ESMO 2020 | Avelumab maintenance for urothelial cancer

VJOncology is committed to improving our service to you

Thomas Powles

Thomas Powles, MBBS, MCRP, Barts Cancer Institute, London, UK, discusses the use of avelumab maintenance in urothelial cancer (UC) as presented at ESMO 2020. Prof. Powles summarizes the use of avelumab first-line (1L) maintenance for patients with advanced UC, highlighting data from the Phase III JAVELIN Bladder 100 trial (NCT02603432). This study showed that avelumab 1L maintenance and best supportive care (BSC) prolonged the overall survival (OS) vs BSC alone in UC patients free from disease progression following 1L induction chemotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter